Brenda J Weigel

Department of Pediatric Oncology, Roswell Park Comprehensive Cancer Center, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, USA.

View Article and Find Full Text PDF

September 2018

A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314).

Authors:

Eric S Schafer Rachel E Rau Stacey Berg Xiaowei Liu Charles G Minard David D'Adamo Rachael Scott Larisa Reyderman Gresel Martinez Sandhya Devarajan Joel M Reid Elizabeth Fox Brenda J Weigel Susan M Blaney

Pediatr Blood Cancer 2018 08 2;65(8):e27066. Epub 2018 May 2.

Department of Pediatrics/Oncology, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.

View Article and Find Full Text PDF

August 2018

A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group.

Authors:

Meredith K Chuk Brigitte C Widemann Charles G Minard Xiaowei Liu AeRang Kim Melanie Brooke Bernhardt Rachel A Kudgus Joel M Reid Stephan D Voss Susan Blaney Elizabeth Fox Brenda J Weigel

Pediatr Blood Cancer 2018 08 25;65(8):e27077. Epub 2018 Apr 25.

Department of Pediatrics, Hem/Onc/BMT/University of Minnesota/Masonic Cancer Center, Minneapolis, MN, USA.

View Article and Find Full Text PDF

August 2018

Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213).

Authors:

Robin E Norris Elizabeth Fox Joel M Reid Andrew Ralya Xiaowei W Liu Charles Minard Brenda J Weigel

Pediatr Blood Cancer 2018 05 2;65(5):e26944. Epub 2018 Jan 2.

University of Minnesota Medical Center/Masonic Center Minneapolis, Minneapolis, Minnesota.

View Article and Find Full Text PDF

May 2018

Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials.

Authors:

Wendy B London Rochelle Bagatell Brenda J Weigel Elizabeth Fox Dongjing Guo Collin Van Ryn Arlene Naranjo Julie R Park

Cancer 2017 Dec 8;123(24):4914-4923. Epub 2017 Sep 8.

Seattle Children's Hospital, Seattle, Washington.

View Article and Find Full Text PDF

December 2017

Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.

Authors:

Yael P Mossé Stephan D Voss Megan S Lim Delphine Rolland Charles G Minard Elizabeth Fox Peter Adamson Keith Wilner Susan M Blaney Brenda J Weigel

J Clin Oncol 2017 Oct 8;35(28):3215-3221. Epub 2017 Aug 8.

Yael P. Mossé, Megan S. Lim, Delphine Rolland, Elizabeth Fox, and Peter Adamson, University of Pennsylvania, Philadelphia, PA; Stephan D. Voss, Harvard Medical School, Boston, MA; Charles G. Minard and Susan M. Blaney, Baylor College of Medicine, Houston, TX; Keith Wilner, Pfizer Oncology, La Jolla, CA; and Brenda J. Weigel, University of Minnesota Cancer Center, Minneapolis, MN.

View Article and Find Full Text PDF

October 2017

Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.

Authors:

Erin R Rudzinski James R Anderson Yueh-Yun Chi Julie M Gastier-Foster Caroline Astbury Frederic G Barr Stephen X Skapek Douglas S Hawkins Brenda J Weigel Alberto Pappo William H Meyer Michael A Arnold Lisa A Teot David M Parham

Pediatr Blood Cancer 2017 Dec 18;64(12). Epub 2017 May 18.

Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles and Keck School of Medicine, University of Southern California, Los Angeles, California.

View Article and Find Full Text PDF

December 2017

A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Authors:

James I Geller John P Perentesis Xiaowei Liu Charles G Minard Rachel A Kudgus Joel M Reid Elizabeth Fox Susan M Blaney Brenda J Weigel

Pediatr Blood Cancer 2017 Nov 27;64(11). Epub 2017 Apr 27.

Masonic Children's Hospital, University of Minnesota Medical Center, Minneapolis, MN.

View Article and Find Full Text PDF

November 2017

A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114).

Authors:

Susan R Rheingold Sarah K Tasian James A Whitlock David T Teachey Michael J Borowitz Xiaowei Liu Charles G Minard Elizabeth Fox Brenda J Weigel Susan M Blaney

Br J Haematol 2017 05 14;177(3):467-474. Epub 2017 Mar 14.

Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.

View Article and Find Full Text PDF

May 2017

First-dose and steady-state pharmacokinetics of orally administered crizotinib in children with solid tumors: a report on ADVL0912 from the Children's Oncology Group Phase 1/Pilot Consortium.

Authors:

Frank M Balis Patrick A Thompson Yael P Mosse Susan M Blaney Charles G Minard Brenda J Weigel Elizabeth Fox

Cancer Chemother Pharmacol 2017 Jan 28;79(1):181-187. Epub 2016 Dec 28.

The Children's Hospital of Philadelphia, 3501 Civic Center Blvd, CTRB-4024, Philadelphia, PA, 19104, USA.

View Article and Find Full Text PDF

January 2017

Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.

Authors:

Brenda J Weigel Elizabeth Lyden James R Anderson William H Meyer David M Parham David A Rodeberg Jeff M Michalski Douglas S Hawkins Carola A S Arndt

J Clin Oncol 2016 Jan 26;34(2):117-22. Epub 2015 Oct 26.

Brenda J. Weigel, University of Minnesota, Minneapolis; Carola A.S. Arndt, Mayo Clinic, Rochester, MN; Elizabeth Lyden, Nebraska Medical Center, Omaha, NE; James R. Anderson, Frontier Science and Technology Research Foundation, Madison, WI; William H. Meyer, University of Oklahoma Health Sciences Center, Oklahoma City, OK; David M. Parham, Children's Hospital of Los Angeles, Los Angeles, CA; David A. Rodeberg, East Carolina University, Greenville, NC; Jeff M. Michalski, Washington University School of Medicine, St Louis, MO; and Douglas S. Hawkins, University of Washington, Seattle, WA.

View Article and Find Full Text PDF

January 2016